Letters to the Editors by Ciaffi, J. et al.
S-165
Letters to the Editors
Clinical and Experimental Rheumatology 2021
COVID-19 vaccine hesitancy 
in systemic sclerosis 
Sirs,
Vaccine hesitancy is defined as the “delay 
in acceptance or refusal of vaccination de-
spite availability of vaccination services” 
(1). The success of COVID-19 vaccination 
programs is a key determinant to abate the 
spread of the infection (2) and understand-
ing what people feel might help to address 
hesitancy (3). Therefore, using the “Oxford 
Covid-19 Vaccine Hesitancy Scale” and 
“Oxford COVID-19 Vaccine Confidence & 
Complacency Scale” (4), we explored the 
attitudes towards COVID-19 vaccine in 
patients with systemic sclerosis (SSc) and 
which sociodemographic or disease-related 
factors might affect hesitancy. A control 
group of individuals affected by inflamma-
tory arthritis was included. 
Translation, linguistic validation and cul-
tural adaptation of the two scales were 
performed according to the WHO best 
practice guidelines (https://www.who.int/
substance_abuse/research_tools/transla-
tion/en/). On the basis of the responses, 
patients were categorised as “clearly posi-
tive”, “very unsure” or “strongly hesitant” 
about COVID-19 vaccine. We included 104 
patients with SSc and 111 controls. Charac-
teristics of the study population are reported 
in Table I.
Seventy-five (72.1%) SSc and 96 (86.5%) 
arthritis patients had “clearly positive” feel-
ings (p=0.009). Respectively, 16 (15.4%) 
and 6 (5.4%) patients were “very unsure” 
(p=0.016), while 3 (2.9%) and 5 (4.5%) had 
a “strongly hesitant” attitude (p=0.531). 
In SSc patients, after stratification for me-
dian age [61.0 (50.25–59.0) years] and 
median disease duration [8.5 (4.0–15.0) 
years], we observed a significant differ-
ence in the hesitancy scale score in older 
vs.younger individuals (11.4±3.6 vs. 
14.5±5.7, p<0.001, Fig 1A) but not in long-
er versus shorter disease duration (12.2±4.4 
vs. 13.8±5.5, p=0.139, Fig 1B). Regarding 
cutaneous involvement, hesitancy scale 
score was lower in patients with higher 
mRSS (11.3±4.0 vs. 14.4±5.5, p=0.003, Fig 
1C) and with diffuse versus limited disease 
subset (10.3±4.1 vs. 13.3±4.9, p=0.022, Fig 
1D). Moreover, individuals with ILD were 
significantly less hesitant than patients with 
no ILD (11.6±4.5 vs. 14.3±5.3, p=0.012, 
Fig 1E) while no difference was retrieved 
according to treatment with immunosup-
pressive therapies or not (13.0±5.0 vs. 
13.0±5.2, p=0.792, Fig 1F).
We found that the majority of SSc patients 
have positive attitudes towards COVID-19 
vaccine. However, compared to inflam-
matory arthritis, less SSc patients have a 
strong intent to receive the vaccination, 
while a higher proportion is doubtful. Our 
data suggest that older individuals and pa-
tients with higher disease activity might 
have more positive feelings about COV-
ID-19 vaccine, similar to previous research 
outlining a lower vaccine hesitancy in peo-
ple at higher risk of severe COVID-19 ill-
ness (4, 5). Interestingly, also the absence 
of differences based on ongoing immuno-
suppressive therapies is consistent with the 
available literature (6-8).
Campochiaro et al. found that 44% of pa-
tients with rheumatic diseases had a clear 
willingness to receive COVID-19 vaccine 
and an additional 37% answered positively 
when recommended by the caring rheuma-
tologist (9). Boekel et al. showed that 61% 
of patients with autoimmune diseases ac-
cepted to receive vaccination against COV-
Table I. General characteristics of patients with systemic sclerosis and controls affected by inflamma-
tory arthritis.
 Systemic sclerosis Inflammatory arthritis p-value
 (n=104)  (n=111) 
Socio-demographic characteristics   
Female, n (%) 90  (86.5) 66  (59.5) <0.001
Age (years), mean (SD) 58.7  (12.9) 55.0  (15.8) 0.060
Age range 18-39 years, n (%) 9  (8.7) 20  (18.0) 0.450
Age range 40-54 years, n (%) 27  (26.0) 29  (26.1) 0.978
Age range 55-69 years, n (%) 48  (46.2) 42  (37.8) 0.217
Age range >69 years, n (%) 20  (19.2) 20  (18.0) 0.819
Employment status   
Employed 44  (42.3) 59  (53.2) 0.112
Homemaker 9  (8.7) 7  (6.3) 0.512
Unemployed 7  (6.7) 7  (6.3) 0.900
Retired 44  (42.3) 38  (34.2) 0.223
Highest level of education   
Middle school, n (%) 46  (44.2) 34  (30.6) 0.039
High school, n (%) 44  (42.3) 48  (43.2) 0.890
University, n (%) 14  (13.5) 29  (26.1) 0.020
Marital status   
Married, n (%) 69  (66.3) 69  (62.2) 0.523
Single, n (%) 22  (21.2) 26  (23.4) 0.690
Cohabiting, n (%) 10  (9.6) 10  (9.0) 0.878
Widowed, n (%) 3  (2.9) 6  (5.4) 0.356
Ever received influenza vaccination, n (%) 65  (62.5) 89  (80.2) 0.004
Ever received pneumococcal vaccination, n (%) 46  (44.2) 62  (55.9) 0.088
Had COVID-19 5  (4.8) 5  (4.5) 0.916
Disease characteristics and therapy   
Disease duration (years), mean (SD) 10.8  (8.3) 12.8  (9.5) 0.101
cDMARDs, n (%) 33  (31.7) 55  (49.5) 0.008
bDMARDs/tsDMARDs, n (%) 2  (1.9) 65  (58.6) <0.001
Glucocorticoids, n (%) 35  (33.7) 20  (18.0) 0.009
Vasoactive therapy, n (%) 98  (94.2)  
Disease subset   
Limited cutaneous SSc, n (%) 71  (68.3)  
Diffuse cutaneous SSc, n (%) 25  (24.0)  
Sine scleroderma SSc, n (%) 8  (7.7)  
Rheumatoid arthritis, n (%)   51  (45.9) 
Psoriatic arthritis, n (%)   44  (39.6) 
Axial spondyloarthritis, n (%)   16  (14.4) 
Disease manifestations in SSc patients   
Interstitial lung disease, n (%) 51  (49.0)  
Digital ulcers, n (%) 58  (55.8)  
Pulmonary arterial hypertension, n (%) 4  (3.8)  
Gastrointestinal involvement, n (%) 29  (27.9)  
Oxford COVID-19 vaccine hesitancy scale score,  13.1  (4.9) 11.5  (4.6) 0.494
    mean (SD) 
Oxford COVID-19 vaccine confidence & 25.2  (6.9) 22.8  (6.0) 0.097 
   complacency scale score, mean (SD) 
Attitude about COVID-19 vaccine   
Clearly positive, n (%) 75  (72.1) 96  (86.5) 0.009
Very unsure, n (%) 16  (15.4) 6  (5.4) 0.016
Strongly hesitant, n (%) 3  (2.9) 5  (4.5) 0.531
HADS-D, mean (SD) 9.0  (3.2) 9.2  (1.6) 0.184
HADS-A, mean (SD) 9.0  (3.3) 8.7  (2.5) 0.487
SF-36 MCS, mean (SD) 59.3  (21.2) 64.3  (23.3) 0.571
SF-36 PCS, mean (SD) 52.9  (24.3) 61.1  (25.1) 0.471
cDMARDs: conventional disease-modifying anti-rheumatic drugs; bDMARDs: biologic disease-modifying anti-
rheumatic drugs; tsDMARDs: targeted synthetic disease-modifying anti-rheumatic drugs; SSc: systemic sclerosis; 
HADS-A: Hospital Anxiety and Depression Scale – Anxiety; HADS-D: Hospital Anxiety and Depression Scale – 
Depression; SF-36: Short Form-36.
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ID-19 (7), while in the international survey 
“VAXICOV”, Felten and colleagues de-
scribed a proportion of 54% of rheumatol-
ogy patients willing to receive COVID-19 
vaccination (8). 
Overall, in our survey clearly positive feel-
ings towards COVID-19 vaccine are more 
frequent than previously reported. How-
ever, besides differences in the question-
naire structure, our survey was conducted 
after the approval in the European Union 
of the first three COVID-19 vaccines and 
it is conceivable that the authorisation posi-
tively affected perception about safety and 
effectiveness in the population. 
In conclusion, our survey suggests that 
most patients with SSc have positive feel-
ings towards COVID-19 vaccine, but un-
certainties are present in a considerable 
proportion of cases. These results highlight 
the crucial role of the caring rheumatolo-
gists in addressing concerns and hesitancy 
of individuals affected by rheumatic diseas-
es with the purpose of promoting vaccine 
literacy and enhancing vaccination rates.
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Fig. 1. Oxford COVID-19 Vaccine Hesitancy Scale score after stratification for median age (A), median disease du-
ration (B), median modified Rodnan skin score (mRSS) (C), diffuse cutaneous (dcSSc) or limited cutaneous (lcSSc) 
subsets (D), presence of interstitial lung disease (ILD) (E), use of immunosuppressive (IS) therapy (F).  
Data are expressed as mean and standard error of the mean.
